Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV Prevention and PrEP Implementation Preferences Among Transgender Women in Malaysia
- 1 December 2020
- journal article
- research article
- Published by SAGE Publications in Transgender Health
- Vol. 5 (4) , 258-266
Abstract
Introduction: Transgender women (TW) face one of the highest HIV burdens worldwide. In Malaysia, 12.4% of TW are HIV infected, ∼30-fold higher than in the Malaysian adult population. Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy, however, little is known about TW's willingness to use PrEP or their preferences for receiving PrEP. This study examined the correlates of Malaysian TW's willingness to use PrEP and their attitudes and preferences related to delivery of PrEP and PrEP-related care. Methods: Between June and August 2017, 361 TW in Malaysia completed an online survey about their knowledge of and willingness to use PrEP for HIV prevention. Results: Only 20.2% of participants had ever previously heard of PrEP and none were currently taking PrEP. The majority (82.5%) expressed high willingness to take PrEP and most participants met the World Health Organization (WHO) indication for PrEP (82.3%). In the multivariate model, lifetime hormone use, prior postexposure prophylaxis use, and having completed a high school education were associated with higher willingness to use PrEP, while injection drug use, older age, and Chinese ethnicity were associated with lower PrEP willingness. Conclusion: TW in Malaysia are highly willing to use PrEP for HIV prevention. Differences in willingness to use PrEP identified by education, ethnicity, substance abuse, and age suggest different strategies may be needed to scale-up PrEP for this diverse community of TW.Keywords
This publication has 28 references indexed in Scilit:
- Prevalence of Human Immunodeficiency Virus and Sexually Transmitted Infections Among Cisgender and Transgender Women Sex Workers in Greater Kuala Lumpur, Malaysia: Results From a Respondent-Driven Sampling StudySexually Transmitted Diseases, 2017
- HIV Prevention Among Transgender Populations: Knowledge Gaps and Evidence for ActionCurrent HIV/AIDS Reports, 2017
- Acceptability of Daily Use of Free Oral Pre-exposure Prophylaxis (PrEP) Among Transgender Women Sex Workers in Shenyang, ChinaAIDS and Behavior, 2017
- PrEP implementation in the Asia‐Pacific region: opportunities, implementation and barriersJournal of the International AIDS Society, 2016
- Global Epidemiology of HIV Infection and Related Syndemics Affecting Transgender PeopleJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- HIV Pre-exposure Prophylaxis Indication and Readiness Among HIV-Uninfected Transgender Women in Ho Chi Minh City, VietnamAIDS and Behavior, 2016
- HIV risk and preventive interventions in transgender women sex workersThe Lancet, 2015
- Worldwide burden of HIV in transgender women: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2013
- Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVNew England Journal of Medicine, 2006
- Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Individuals for Whom Interferon‐α and Lamivudine Therapy Have FailedThe Journal of Infectious Diseases, 2002